Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And so, we have strong conviction that there is a long running opportunity in front of us of robust growth |
| We have a robust GEM-X roadmap ahead, including a comprehensive menu of high-performance assays and applications designed to deliver superior economics and drive broad adoption at large scale |
| And we believe that we have the ability over the long term to get back to higher gross margins |
| 2023 was another strong year for 10x Genomics, with total revenue growing 20% to $619 million, as previously announced |
| Even more importantly, customers have been incredibly enthusiastic about the platform, as they rapidly move from install to insight, from instrument delivery to powerful discoveries |
| We strongly believe in elasticity of demand for our products |
| But by and large, the customers have been coming back to us because our product – due to the superiority of the products, much better data quality, much better workflow, much greater breadth of applications, much greater support, customer support, commercial support, and that is really our goal, as I mentioned earlier, is to keep investing in innovation |
| And that workflow is a much improved version relative to what we started years ago and it's something that has resonated with our customers |
| The results demonstrate Xenium delivers the best sensitivity, the best specificity, the best throughput and the best biological insights |
| They understand we have work to do to get there, and they're fully rallied around our vision of creating a premier commercial organization that delivers superior execution and superior results |
| We believe single cell analysis is nowhere near fully penetrated and that there are significant opportunities ahead, which our new products will help us capture |
| Spatial instrument revenue was $75.6 million compared to $13.8 million in 2022, which was driven by the incredibly strong traction we experienced with Xenium in its first full year |
| Our commercial team is excited and engaged to help customers navigate these product launches and deliver on the full promise of single cell and spatial biology |
| What is really exciting about Xenium is the amount of technological headroom that this platform has ahead – with tremendous runway for more applications, higher throughput, and lower cost over the years |
| Our teamwork and diligence in controlling spend is paying off, and we ended the year on strong financial footing |
| Xenium's exceptional launch year reinforces our belief in the enormous long-term potential for the platform, which we believe will usher in a new era of genomic analysis |
| Xenium is just one of several accomplishments in 2023, validating our strategy to drive growth through innovation and reinforcing we are well positioned for long-term success |
| We believe the momentum of our new products along with a renewed commercial focus on Chromium will help invigorate the franchise and drive more robust performance in 2024 and beyond |
| This cutting-edge facility adds operational scale and capacity to enable multiples of growth |
| The investments we're making in the Chromium franchise to raise the bar and set a new standard for single cell analysis underscore our confidence in the growth opportunity ahead |
| For the rest of the year, we believe we have a number of potential upsides |
| In fact, I think sitting here right now, I can say with full confidence, it's as strong or stronger than it has ever been |
| Our product development innovation engine has demonstrated, at least shown the ability to launch new platforms and new products |
| 10% growth year-over-year at the top line is solid |
| Following this principle, we believe there are large opportunities ahead and our commitment to ongoing product innovation will allow us to capture those opportunities |
| And just think about what we've done over the last year and since launching the CytAssist roughly a year-and-a-half ago where our messaging has been focused on the CytAssist being the future of the Visium platform and that having a really strong adoption curve and a number of strong placement quarters, with a good number of customers who we believe have not just bought it to use Visium, but have also purchased it to be to be ready for Visium HD |
| Second is the upside in Xenium instrument placements |
| Third is the upside related to Visium HD where there is potential for quicker adoption overall and the benefit of driving increased CytAssist placements |
| We kicked off 2024 with the launches of two catalytic new products, which demonstrate the enduring strength and velocity of our innovation engine and its impact and value for customers around the world |
| Overall, we believe we have a great setup to drive positive cash flow for the year while making targeted investments to continue driving growth |
| Statement |
|---|
| Chromium instrument revenue was $11.1 million, down 27% year-over-year |
| Chromium instrument revenue was $47.9 million, down 18% year-over-year |
| It's been one of the major headwinds to growth over the last couple of years, obviously |
| And revenue in APAC was $103.3 million, a 2% decrease year-over-year |
| But in response to a prior question, I think you said that you expected CytAssist instruments to be down year-over-year |
| For Visium, we're expecting instruments to be slightly down year-over-year |
| And as a result, we expect to see a more pronounced step down in placements to start the year |
| So a slight decline in revenue |
| The decrease in gross margin was primarily due to a higher mix of Xenium instruments sold |
| So, for Q1, we do have a more difficult compare considering that |
| That said, and generally expected for major product updates like these, we are anticipating some temporary headwinds while customers evaluate, test and train as part of the transition to these new products |
| The decrease in gross margin was primarily due to changes in product mix due to a higher number of Xenium instruments sold |
| So at the midpoint, for Visium instruments, so CytAssist, that has an assumption of being slightly down year-over-year |
| In the fourth quarter, you were down to like 6% of revenues coming from China and that used to be north of sort of 20% |
| Justin McAnear For China, keep in mind that, in 2023, things started to take a downturn in China beginning in Q2 |
| Operating loss for the fourth quarter of 2023 was $55.2 million compared to a loss of $23.1 million for the fourth quarter of 2022 |
| And as a percent of revenues, it's dropped significantly |
| With any new product, you start off with yields probably a little bit less than where you expect them to be longer term |
| In fact, a customer recently told us that our technologies aren't just unraveling biology; they're unearthing opportunities to create hope |
| This warrants some conservatism around the pace of new product adoption |
Please consider a small donation if you think this website provides you with relevant information